Log in

NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

$85.75
-0.81 (-0.94 %)
(As of 03/29/2020 03:20 PM ET)
Today's Range
$82.15
Now: $85.75
$88.16
50-Day Range
$72.48
MA: $104.07
$129.96
52-Week Range
$67.98
Now: $85.75
$196.00
Volume305,223 shs
Average Volume710,667 shs
Market Capitalization$2.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.12
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More
GW Pharmaceuticals PLC- logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees791
Market Cap$2.65 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.


GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

How has GW Pharmaceuticals PLC-'s stock been impacted by COVID-19 (Coronavirus)?

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GWPH shares have decreased by 1.3% and is now trading at $85.75. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for GW Pharmaceuticals PLC-.

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.32. The biopharmaceutical company had revenue of $109.10 million for the quarter, compared to analyst estimates of $80.92 million. GW Pharmaceuticals PLC- had a negative return on equity of 16.12% and a negative net margin of 2.90%. The company's revenue for the quarter was up 1528.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) EPS. View GW Pharmaceuticals PLC-'s earnings history.

What price target have analysts set for GWPH?

13 analysts have issued twelve-month target prices for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $134.00 to $260.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $198.42 in the next year. This suggests a possible upside of 131.4% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

News headlines about GWPH stock have trended positive on Sunday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of 2.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutGW Pharmaceuticals PLC-.

Are investors shorting GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 5,250,000 shares, a decline of 6.9% from the February 13th total of 5,640,000 shares. Based on an average trading volume of 609,800 shares, the days-to-cover ratio is presently 8.6 days. Approximately 17.1% of the shares of the stock are sold short. View GW Pharmaceuticals PLC-'s Current Options Chain.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Tesla (TSLA), Cronos Group (CRON), Walt Disney (DIS) and Intel (INTC).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the following people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by many different institutional and retail investors. Top institutional investors include Capital Research Global Investors (11.73%), Franklin Resources Inc. (7.42%), Franklin Resources Inc. (7.42%), Capital World Investors (3.58%), Victory Capital Management Inc. (3.15%) and Victory Capital Management Inc. (3.15%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-.

Which institutional investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Lord Abbett & CO. LLC, Credit Suisse AG, Renaissance Technologies LLC, Marshall Wace LLP, DekaBank Deutsche Girozentrale, Schonfeld Strategic Advisors LLC, and Redwood Investments LLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz, and William A Waldegrave. View insider buying and selling activity for GW Pharmaceuticals PLC-.

Which institutional investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was purchased by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Franklin Resources Inc., Franklin Resources Inc., Janus Henderson Group PLC, Eventide Asset Management LLC, Capital World Investors, Fred Alger Management LLC, and Parkman Healthcare Partners LLC. View insider buying and selling activity for GW Pharmaceuticals PLC-.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $85.75.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $2.65 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. View additional information about GW Pharmaceuticals PLC-.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  792 (Thanks for Voting!)
Underperform Votes:  522 (Thanks for Voting!)
Total Votes:  1,314
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel